Glyphosate Litigation Facts
  • Five-Point Plan
  • Settlement Overview
  • Litigation Overview
    • Filings and Rulings
  • Resources
  • Media Center
    • Media Statements
    • In The News
Glyphosate Litigation Facts
  • Five-Point Plan
  • Settlement Overview
  • Litigation Overview
    • Filings and Rulings
  • Resources
  • Media Center
    • Media Statements
    • In The News
Glyphosate Litigation Facts
  • Five-Point Plan
  • Settlement Overview
  • Litigation Overview
    • Filings and Rulings
  • Resources
  • Media Center
    • Media Statements
    • In The News
  1. Home
  2. Media Statements
  3. Bayer Statement on Hardeman Trial in San Francisco Opening

Bayer Statement on Hardeman Trial in San Francisco Opening

February 25, 2019 in Media Statements

The following is Bayer’s statement regarding the commencement of the Hardeman glyphosate-based herbicide trial before Judge Vince Chhabria of the U.S. District Court for the Northern District of California. This is the first case in the glyphosate federal multi-district litigation (MDL) to go to trial.

“While we have great sympathy for Mr. Hardeman, the extensive body of scientific research on glyphosate-based herbicides over four decades supports the conclusion that Roundup is not responsible for his illness.

“Glyphosate-based herbicides have been used safely and successfully for over four decades worldwide and are a valuable tool to help farmers deliver crops to markets and practice sustainable farming by reducing soil tillage, soil erosion and carbon emissions. There is an extensive body of research on glyphosate and glyphosate-based herbicides, including more than 800 rigorous studies submitted to EPA, European and other regulators in connection with the registration process, that confirms that these products are safe when used as directed. Notably, the largest and most recent epidemiologic study – the 2018 independent National Cancer Institute-supported long-term study that followed over 50,000 pesticide applicators for more than 20 years and was published after the IARC monograph – found no association between glyphosate-based herbicides and cancer. Additionally, EPA’s 2017 post-IARC cancer risk assessment examined more than 100 studies the agency considered relevant and concluded that glyphosate is ‘not likely to be carcinogenic to humans,’ its most favorable rating.”

January 2, 2020
HardemanMDL
SHARE
  • Email
  • Twitter
  • Facebook
  • Google +
  • Pinterest
  • Tumblr
  • Linkedin
  • Vkontakte
  • WhatsApp
Category
  • Filings and Rulings
  • Five-Point Plan
  • In The News
  • Media Statements
  • Resources
    • Documents
    • Infographics
  • Uncategorized
Tags
Ads alesi Benefits carson ferro five-point plan Hardeman Infographics JCCP Johnson MDL Ninth Circuit Pilliod Prop 65 Regulators Roundup Science Settlement Shelton St. Louis City Supreme Court of California

Five-Point Plan to address potential future Roundup™ claims

Bayer today provided an update on its five-point plan to address future Roundup™ litigation risk after its May 27th decision to withdraw from the national class process. The company is now in more control of important aspects of the risk mitigation process and has sketched out two basic scenarios going forward to provide a path to closure of this litigation. The first scenario is based on obtaining a favorable decision by the United States Supreme Court on a cross-cutting issue like federal preemption which would effectively and largely end the U.S. Roundup™ litigation. The second scenario assumes that the Supreme Court either declines to hear the Hardeman case or issues a ruling in favor of plaintiff – in that case the company would activate its own claims administration program.

Read about the five-point plan here.

Copyright © 2021, All Rights Reserved
Imprint
Privacy Statement

This site was prepared by the Bayer Group for educational purposes only.
For more information on glyphosate herbicides, visit: https://www.bayer.com/en/glyphosate-roundup.aspx.

Copyright © 2019, All Rights Reserved
  • Five-Point Plan
  • Settlement Overview
  • Litigation Overview
  • Resources
  • Media Center